Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ras”

843 pharma patents match "ras" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 843
Index total 30,257
Page 2 / 36

Quick answer

This filtered view shows 843 pharmaceutical patents matching "ras" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

843 results for “ras” · 30,257 patents in full index Clear search

  1. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  2. US 12391742

    Anti-KRAS-G12D T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  3. US 12390512

    Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae

    SHANGHAI REINOVAX BIOLOGICS CO., LTD · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  4. WO 2025169901

    CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE PRÉSENTANT UNE ACTIVITÉ D'INDUCTION DE LA DÉCOMPOSITION DE PROTÉINES MUTANTES KRAS

    ASTELLAS PHARMA INC [JP] · Granted Aug 14, 2025 · Expires Aug 9, 2045

    granted
  5. US 12384750

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  6. US 12383652

    Nanofiber structures and methods of manufacture and use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  7. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  8. US 12383627

    Antimicrobial scaffolds

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  9. WO 2025159142

    COMPOSÉ HÉTÉROCYCLIQUE POUR INDUIRE LA DÉGRADATION DE LA PROTÉINE KRAS

    ASTELLAS PHARMA INC [JP] · Granted Jul 31, 2025 · Expires Jul 26, 2045

    granted
  10. US 12364685

    Isoxazoline parasiticide formulations

    Tarsus Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  11. US 12311016

    Biomarkers and immunogenic compositions for filarial parasites

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 27, 2025 · Expires May 22, 2045

    granted
  12. US 12310929

    Use of rasagiline for the treatment of restless legs syndrome

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  13. US 12310944

    Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted May 27, 2025 · Expires May 22, 2045

    granted
  14. US 12312391

    Anti-mutated KRAS T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 27, 2025 · Expires May 22, 2045

    granted
  15. US 12312334

    Quinoxaline compounds and uses thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted May 27, 2025 · Expires May 22, 2045

    granted
  16. US 12304940

    HLA class II-restricted t cell receptors against mutated RAS

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 20, 2025 · Expires May 15, 2045

    granted
  17. US 12297447

    Gene therapy for juvenile Batten disease

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted May 13, 2025 · Expires May 8, 2045

    granted
  18. US 12291502

    Topoisomerase II-alpha inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted May 6, 2025 · Expires May 1, 2045

    granted
  19. US 12286431

    Crystalline forms of a KRas G12C inhibitor

    Mirati Therapeutics, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  20. US 12280113

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  21. US 12281113

    Crystalline forms of a KRas G12C inhibitor

    Mirati Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  22. US 12279630

    Treatment and prevention of seed allergies

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  23. US 12263250

    Nanofiber segments and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  24. US 12257306

    Antiviral prodrugs and nanoformulations thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted